Life Sciences Virtual Investor Forum to Showcase Diverse Pipeline of Therapies and Diagnostics on September 17

Investors seeking direct insight into emerging life sciences companies will have an opportunity on September 17, 2026, when the Life Sciences Virtual Investor Forum convenes online. Hosted by Virtual Investor Conferences and marketed by B2i Digital, Inc., the event features a global lineup of companies presenting 30-minute sessions followed by audience Q&A. The forum’s diverse agenda spans photothermal cancer therapy, cannabinoid-based formulations, precision drug delivery, a new class of antibiotics, a humanized monoclonal antibody for solid tumors, Focal Adhesion Kinase inhibitors for cancer and fibrosis, and FDA-cleared four-dimensional respiratory imaging.

The breadth of technologies on display underscores the event’s importance for investors tracking innovation across multiple therapeutic areas. Sona Nanotech Inc. will present its photothermal cancer therapy built on gold nanorods, while Raphael Pharmaceutical brings cannabinoid-based formulations in development for rheumatoid arthritis, chronic lung inflammation, and autoimmune disease. Adaptin Bio, Inc. will highlight precision drug delivery technologies aimed at target tissues including behind the blood-brain barrier. Acurx Pharmaceuticals, Inc. is developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens, addressing a critical unmet need in infectious disease. CytoDyn Inc. will discuss its humanized monoclonal antibody being studied in solid-tumor oncology, and Amplia Therapeutics Ltd. will present its pipeline of Focal Adhesion Kinase inhibitors for cancer and fibrosis. 4DMedical Ltd. rounds out the lineup with its FDA-cleared four-dimensional respiratory imaging.

David Shapiro, Chief Executive Officer of B2i Digital, Inc., emphasized the value of live interaction: “Reading company filings is a great cure for insomnia, but if you want to stay awake and hear it directly from management, these conferences are the best way to get a real feel for the company. My favorite part is the Q&A and hearing how they handle the impromptu questions that are really on your mind.” The Q&A sessions allow investors to probe management on strategy, clinical progress, and market potential in real time.

The forum’s reach is amplified by B2i Digital’s media network, which spans over 800 news, broadcast, and trade outlets with a combined monthly audience exceeding 330 million, plus more than 1.7 million followers and 70,000 opt-in email subscribers. This broad exposure can raise the profile of presenting companies and potentially attract new investor interest. Event details and presenting company profiles are available at https://b2idigital.com/sept-17-life-sciences-virtual-investor-forum. Investors can register at https://www.virtualinvestorconferences.com/wcc/eh/4814904/category/150412/september-17th-life-sciences-virtual-investor-forum?utm_source=b2i&utm_medium=marketing&utm_campaign=0917SeptLifeScienceVIC.

Replays will be available on the B2i Digital and OTC Markets YouTube channels, extending the event’s utility beyond the live sessions. Virtual Investor Conferences, an OTC Markets Group Inc. property, regularly features public companies from exchanges worldwide, including NYSE, Nasdaq, TSX, TSXV, CSE, ASX, LSE, and OTC Markets. For life sciences companies, the forum offers an efficient way to engage a broad investor audience without the cost and travel of in-person events. For investors, it provides a rare chance to hear directly from management teams and ask questions that matter. More information about B2i Digital’s Featured Conferences and other programs is available at https://b2idigital.com.